MAM
Ignite Mudra wins GRL mandate
MUMBAI:Govind Rubber has appointed Ignite Mudra as its strategic branding partner.
The long-term partnership is to pursue GRL‘s growth ambitions in the bicycle tyres and allied businesses.
GRL director Rahul Poddar said, “The last decade has seen some exciting changes in the bicycle market and the scenario today is very challenging. We believe that with a partner like Ignite Mudra, we can grow the business and create a powerful brand name for ourselves. Ignite Mudra will also be assisting us in our ventures into other related businesses. We‘re looking forward to a long-term relationship with them.”
A global name in the bicycle tyres market, GRL is a part of the SiyaramPoddar conglomerate which has interests in tyres, textiles, garments and furnishings.
Ignite Mudra head Sudarshan Banerjee said, “GRL is a prestigious win for us. The brand is a leader in its business and has a huge potential for growth. The challenges presented by the category are right up the Ignite Mudra alley. We believe that some truly exciting work can be done and look forward to the journey ahead.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
